HPV-DNA整合状态与宫颈癌发生发展及抑癌基因p53、pRb表达的相关性

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (2): 155-159.

HPV-DNA整合状态与宫颈癌发生发展及抑癌基因p53、pRb表达的相关性

温川松，仝进毅

浙江省杭州市第一人民医院，南京医科大学附属杭州医院妇科，杭州 310000，浙江

收稿日期:2016-08-10 修回日期:2016-12-19 出版日期:2017-02-26 发布日期:2017-03-02
作者简介:温川松，女，本科，副主任医师，研究方向：妇科肿瘤。 Tel：15867187766 E-mail：yh-141107@163.com
基金资助:
浙江省自然科学基金项目（LY12H16018）

Correlation between HPV-DNA integration and cervical cancer development as well as the expression of cancer suppressor gene p53 and pRb

WEN Chuansong, TONG Jinyi

Department of Gynaecology, First People's Hospital of Hangzhou (Hangzhou Hospital Affiliated to Nanjing Medical University), Hangzhou 310000, Zhejiang, China

Received:2016-08-10 Revised:2016-12-19 Online:2017-02-26 Published:2017-03-02

摘要/Abstract

摘要：

目的:分析人乳头瘤病毒（HPV）-DNA整合状态与宫颈癌发生发展及抑癌基因p53、pRb表达的关系，为其临床诊治提供新思路。方法: 取本院收治、手术治疗的宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN）和宫颈癌患者131例，根据病变程度分为CINⅠ、CINⅡ、CINⅢ和宫颈癌4组，取同期收治的良性瘤患者33例为对照，术中留取病理组织，采用全基因组测序和高通量病毒整合实验观察HPV-DNA整合状态。进一步根据整合状态分为多重整合、单重整合和无整合3组，采用免疫组织化学实验观察抑癌基因p53、pRb的表达水平。结果: 各组HPV-DNA整合率不同，自健康组织、CINⅠ、CINⅡ、CINⅢ、宫颈癌的顺序依次升高，且宫颈癌以多重整合为主，健康组织和CIN以单一整合为主，组间差异有统计学意义（P<0.05）。本次考察发现HPV16、HPV58、HPV18、HPV35、HPV31、HPV33、HPV52、HPV51 8种高危HPV整合类型，在各组中的分布趋势大体一致。不同整合状态的p53、pRb阳性率和表达水平明显不同，无整合组高于单重整合组，单重整合组高于多重整合组，其组间差异均有统计学意义（P<0.05）。结论:HPV-DNA整合能抑制p53与pRb的局部表达，促进宫颈癌发展，对宫颈癌鉴别和预后评估有一定的指导作用。

关键词: 人乳头瘤病毒, DNA整合, 宫颈癌, 抑癌基因

Abstract:

AIM: To analyze the correlation between HPV-DNA integration and cervical cancer development as well as the expression of cancer suppressor gene p53 and pRb, so as to provide new idea for its clinical diagnosis and treatment. METHODS: 131 patients with cervical intraepithelial neoplasias (CIN) and cervical cancer which treated with surgery were selected and divided into 4 groups according to disease degree: CINⅠ, CINⅡ, CINⅢ and cervical cancer;at the same time, 33 patients with benign tumor were selected as controls. The pathological tissues were extracted and detected HPV-DNA integration using whole genome sequencing and high-throughput virus integrated experiment. According to HPV-DNA integration results, all the patients were divided into 3 groups: multi-integration, single-integration and non-integration, and the p53 and pRb expression levels between groups were compared.RESULTS:The HPV-DNA integration rate increased according to the healthy tissue, CIN Ⅰ, CIN Ⅱ, CIN Ⅲ, cervical cancer in the order, and there was mainly multi-integration in the cervical cancer, and mainly single-integration in CIN and the controls, the difference between groups had statistical significance (P<0.05). 8 types of high-risk HPV-DNA integration, including HPV16, HPV58, HPV18, HPV35, HPV31, HPV33, HPV52 and HPV51 were found, with similar distribution trend in different disease degree. The p53 and pRb positive rate and expression level were different in different integration state, and non-integration group was higher than single-integration group, single-integration group was higher than multi-integration group, the difference between groups had statistical significance (P<0.05).CONCLUSION:HPV-DNA integration can restrain the expression of p53 and pRb and promote the development of cervical cancer, which may have a certain guiding role for the identification and prognosis evaluation of cervical cancer.

Key words: human papilloma virus, DNA integratio, cervical cancer, cancer suppressor gene

中图分类号:

R968
R737.3

温川松，仝进毅. HPV-DNA整合状态与宫颈癌发生发展及抑癌基因p53、pRb表达的相关性[J]. 中国临床药理学与治疗学, 2017, 22(2): 155-159.

WEN Chuansong, TONG Jinyi. Correlation between HPV-DNA integration and cervical cancer development as well as the expression of cancer suppressor gene p53 and pRb[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 155-159.

参考文献

［1］李慧弘, 肖长义. HPV DNA整合、E2破坏、HPV E2/E6比值与宫颈癌关系的研究［J］. 中国免疫学杂志, 2010, 26(7): 670-673.
［2］吴赵易, 曹佩霞. 高危型人乳头瘤病毒感染的中西医治疗［J］. 长春中医药大学学报, 2014, 30(4): 657-659.
［3］Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test［J］. J Clin Microbiol, 2011, 49(7): 2643-2650.
［4］Wongworawat Y, Filippova M, Williams VM, et al. Chronic oxidative stress increases the integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes［J］. Am J Cancer Res, 2016, 6(4): 764-780.
［5］张敏鸽,刘明晖. 高危HPV与宫颈癌发生的相关性［J］. 实用癌症杂志,2012, 27(6): 670-672.
［6］Origoni M, Cristoforoni P, Carminati G, et al. E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective［J］. Ecancermedicalscience, 2015, 9: 533.
［7］王丽. 人乳头瘤病毒整合状态与宫颈上皮内瘤变及宫颈癌的相关性研究［D］. 青岛大学, 2015.
［8］Schmitz M, Driesch C, Jansen L, et al. Non-random integration of the HPV genome in cervical cancer［J］. PLoS ONE, 2012, 7(6): e39632.
［9］豆道勤, 张东红. 高危型人乳头瘤病毒整合在宫颈癌变中的作用机制和临床检测进展［J］. 中国实用妇科与产科杂志, 2011, 27(8): 629-631.
［10］诸海燕, 金纬纬, 胡燕, 等. 53BP1在宫颈癌组织中的表达及其与P53和HPV感染的关系［J］. 医学研究杂志, 2013, 42(2): 124-127.
［11］Liu Y, Lu Z, Xu R, et al. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology［J］. Oncotarget, 2016, 7(5): 5852-5864.
［12］欧阳密霞, 胡媛, 曾飞. ASPP2,iASPP和p53在宫颈癌组织中的表达及意义［J］. 中南大学学报(医学版), 2015, 40(3): 256-260.
［13］劳小斌, 刘晓强, 邱春嫦. 宫颈癌患者人乳头状瘤病毒16型感染与P53基因表达及临床意义［J］. 中华医院感染学杂志, 2013, 23(24): 5918-5920.
［14］Liu X, Yang WT, Zheng PS. Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas［J］. Oncotarget, 2014, 5(21): 10870-10885.
［15］喻珊, 王鹤林, 宋增武, 等. P53,P16,PRb的表达与宫颈上皮病理改变的关系［J］. 江西医药, 2011, 46(2): 120-122.

[1]	陈星，吴为玲，陈姗姗，叶丽娅，梅双双，王静，何钰，柴泽英. 基于肿瘤相关巨噬细胞的宫颈癌免疫学病理机制研究[J]. 中国临床药理学与治疗学, 2017, 22(12): 1394-1399.
[2]	赵巧云，范广民，阮正英，应香岚. PTEN和BID在宫颈癌组织中的表达及意义[J]. 中国临床药理学与治疗学, 2016, 21(11): 1246-1250.
[3]	刘健，崔艳艳，李胜泽，刘红丽，李玉芝，郭苏阳，刘静. 阿司匹林诱导宫颈癌Hela细胞凋亡及抑制增殖的机制研究[J]. 中国临床药理学与治疗学, 2016, 21(11): 1263-1266.
[4]	周琴, 杨小姣, 石孟琼, 刘英, 覃慧林, 冯天艳, 张永峰, 尉小琴. 南赤瓟醇提物通过PI3K/Akt/mTOR信号通路促进人宫颈癌Caski细胞凋亡[J]. 中国临床药理学与治疗学, 2016, 21(1): 42-49.
[5]	郑颖. MiR-193b体外协同增强顺铂对宫颈癌细胞的抗肿瘤效应[J]. 中国临床药理学与治疗学, 2015, 20(8): 896-900.
[6]	李永铮, 陈伟. 三羟基异黄酮通过AMPK 和 mTOR信号通路对宫颈癌细胞抑制作用的研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 15-22.
[7]	唐修武, 孙云, 倪观太. 保留盆腔神经宫颈癌根治术与传统宫颈癌根治术的比较研究[J]. 中国临床药理学与治疗学, 2013, 18(10): 1148-1154.
[8]	胡旻, 邵明君, 何云芹, 周梦熊. 吉西他滨新辅助化疗在宫颈癌中的近期效果观察[J]. 中国临床药理学与治疗学, 2010, 15(4): 454-457.
[9]	徐道华, 周晨慧, 夏永鹏, 邱宗荫, 贾正才, 周伟. 宫颈癌治疗性多肽疫苗的合成及其诱导细胞毒性T 淋巴细胞效应的研究[J]. 中国临床药理学与治疗学, 2007, 12(2): 200-203.
[10]	李从铸, 翟玉霞. 国产重组人粒细胞集落刺激因子在妇科恶性肿瘤化疗中的应用[J]. 中国临床药理学与治疗学, 2004, 9(11): 1301-1304.